Mantle cell lymphoma – Current standards of care and future directions
Peter Martin(Northwestern University), Martin Dreyling(LMU Klinikum), Paola Ghione(University of Turin)
Cited by 17
Related Papers
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
|New England Journal of Medicine|2014|1.1k
Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results
|Blood|2015|408
Outcome of Deferred Initial Therapy in Mantle-Cell Lymphoma
|Journal of Clinical Oncology|2009|340
Bortezomib Plus CHOP-Rituximab for Previously Untreated Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma
|Journal of Clinical Oncology|2010|319